Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | MAPKAPK5 | Q8IW41 | 6/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | WEE1 | P30291 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469708 | 0.94 | TTK (0.52) | TTKSRCAURKAIGF1RWEE1 | |
| SCHEMBL1674141 | 0.85 | AURKA (0.44) | AURKAMAPKAPK5FYNBACE1BACE2 | |
| SCHEMBL1674131 | 0.84 | MAPKAPK5 (0.48) | TTKAURKAMAPKAPK5 | |
| SCHEMBL13321417 | 0.83 | TTK (0.43) | TTKAURKABACE1BACE2 | |
| SCHEMBL1674040 | 0.80 | AURKA (0.47) | AURKAMAPKAPK5MAPK8 | |
| SCHEMBL1674223 | 0.80 | CD38 (0.43) | AURKAMAPKAPK5FYN | |
| SCHEMBL11939502 | 0.79 | BACE1 (0.44) | TTKAURKAMAPKAPK5BACE1BACE2 | |
| SCHEMBL2678424 | 0.79 | MAPKAPK5 (0.40) | TTKMAPKAPK5BACE1BACE2 | |
| SCHEMBL1673999 | 0.78 | MAPKAPK5 (0.67) | AURKAIGF1RMAPKAPK5FYNSYK | |
| SCHEMBL1674062 | 0.78 | TP53 (0.48) | TTKMAPKAPK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138193-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-8138193-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-8138193-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-8133895-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-13 | — | — | US | disclosed |
| US-8133895-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-13 | — | — | US | disclosed |
| US-20100240666-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-09-23 | — | — | US | disclosed |
| US-20100240666-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-09-23 | — | — | US | disclosed |
| US-20100240666-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-09-23 | — | — | US | disclosed |
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | GALAPAGOS, N.V. (BE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | GALAPAGOS, N.V. (BE) | 2009-05-21 | — | — | US | disclosed |
| WO-2008138843-A1 | IMIDAZOPYRIDINES AND TRIAZOLOPYRIMIDINES USEFUL FOR THE TREATMENT OF JOINT DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008138843-A1 | IMIDAZOPYRIDINES AND TRIAZOLOPYRIMIDINES USEFUL FOR THE TREATMENT OF JOINT DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | NOD1, TNF, NOD2 | TTK 4697/4885SRC 4688/4885AURKA 4025/4885 |
| US-20100240666-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | RRP15, RARS2, RO60 | TTK 4724/4885SRC 4473/4885AURKA 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.